Please try another search
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Name | Age | Since | Title |
---|---|---|---|
Gang Lu | 49 | 2014 | Director |
Wendy Hayes | 52 | 2020 | Independent Director |
Feng Deng | 59 | 2016 | Director |
Licen Lisa Xu | 57 | 2022 | Independent Director |
Min-Jui Shen | 58 | 2020 | Independent Director |
Jinxiang Li | 38 | 2019 | CFO, Compliance Officer & Director |
Yusheng Han | 44 | - | Founder, Chairman & CEO |
Zhihong Zhang | 47 | 2016 | CTO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review